Skip to main content

Advertisement

SpringerLink
Log in

How to Sequence Therapies in Mycosis Fungoides

  • Lymphoma (JL Muñoz, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205 e1–16; quiz 21–2.

  2. Kaufman AE, Patel K, Goyal K, O’Leary D, Rubin N, Pearson D, et al. Mycosis fungoides: developments in incidence, treatment and survival. J Eur Acad Dermatol Venereol. 2020;34(10):2288–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295–9.

    Article  PubMed  Google Scholar 

  4. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223 e1–17; quiz 40–2.

  5. Primary Cutaneous Lymphomas (Version 1.2021): National Comprehensive Cancer Network; [Available from: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf.

  6. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer. 2017;77:57–74.

    Article  PubMed  Google Scholar 

  7. Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020;7:CD008946.

  8. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22.

    Article  CAS  PubMed  Google Scholar 

  9. •• Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020. A prospective study of an international database of 395 patients with stage IA–IIA MF found that higher disease stage and the presence of plaques or folliculotropism prompt initiation of systemic therapies by physicians; however, skin-directed therapy was superior to systemic therapy even in patients with these disease characteristics.

  10. Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019;9:260.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Farber EM, Cox AJ, Steinberg J, McClintock RP. Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing. Cancer. 1966;19(2):237–45.

    Article  CAS  PubMed  Google Scholar 

  12. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134(8):949–54.

  13. Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16(4):283–7.

    Article  PubMed  Google Scholar 

  14. •• Kartan S, Shalabi D, O'Donnell M, Alpdogan SO, Sahu J, Shi W, et al. Response to topical corticosteroid monotherapy in mycosis fungoides. J Am Acad Dermatol. 2021;84(3):615–23.A retrospective review of topical corticosteroid monotherapy in 163 patients with any stage MF revealed a response rate of 73% and decreases in BSA and mSWAT scores of 65% and 67%, respectively.

  15. Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician. 1990;41(5):1531–8.

    CAS  PubMed  Google Scholar 

  16. Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288–98.

    Article  PubMed  Google Scholar 

  17. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32.

  18. •• Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021. This prospective observational study of mechlorethamine gel as part of combination therapy in 298 patients with MF found response rates of 44–45% at 12 months with peak responses occurring at 18 months.

  19. Gordon MC, Sluzevich JC, Jambusaria-Pahlajani A. Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod. JAAD Case Rep. 2015;1(6):348–50.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Shipman AR, Scarisbrick J. New treatment options for mycosis fungoides. Indian J Dermatol. 2016;61(1):119.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275–80.

    Article  PubMed  Google Scholar 

  22. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther. 2006;19(5):264–71.

    Article  CAS  PubMed  Google Scholar 

  23. Nguyen CV, Bohjanen KA. Skin-directed therapies in cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):683–96.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002;8(5):1234–40.

    CAS  PubMed  Google Scholar 

  25. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–32.

    Article  CAS  PubMed  Google Scholar 

  26. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15.

    Article  PubMed  Google Scholar 

  27. Besner Morin C, Roberge D, Turchin I, Petrogiannis-Haliotis T, Popradi G, Pehr K. Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-cell lymphoma. J Cutan Med Surg. 2016;20(3):244–8.

  28. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50(4):600–7.

  29. Hodak E, Pavlovsky L. Phototherapy of mycosis fungoides. Dermatol Clin. 2015;33(4):697–702.

    Article  PubMed  CAS  Google Scholar 

  30. Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, et al. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides. Eur J Dermatol. 2016;26(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  31. Olisova OY, Megna M, Grekova EV, Zaslavsky DV, Gorenkova LG, Sidikov AA, et al. PUVA and interferon alpha2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. J Eur Acad Dermatol Venereol. 2019;33(2):e72–4.

    Article  CAS  PubMed  Google Scholar 

  32. Vieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacol Ther. 2020;222:107784.

  33. Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27–58.

    Article  PubMed  Google Scholar 

  34. Ahmad K, Rogers S, McNicholas PD, Collins P. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. Acta Derm Venereol. 2007;87(5):413–7.

    Article  CAS  PubMed  Google Scholar 

  35. Briffa DV, Warin AP, Harrington CI, Bleehen SS. Photochemotherapy in mycosis fungoides. A study of 73 patients. Lancet. 1980;2(8185):49–53.

  36. Raphael BA, Morrissey KA, Kim EJ, Vittorio CC, Rook AH. Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;65(1):212–4.

    Article  PubMed  Google Scholar 

  37. Nikolaou V, Sachlas A, Papadavid E, Economidi A, Karambidou K, Marinos L, et al. Phototherapy as a first-line treatment for early-stage mycosis fungoides: the results of a large retrospective analysis. Photodermatol Photoimmunol Photomed. 2018;34(5):307–13.

    Article  CAS  PubMed  Google Scholar 

  38. Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol. 2009;60(1):39–50.

    Article  PubMed  Google Scholar 

  39. Atci T, Baykal C. Efficacy of narrow-band ultraviolet-B therapy in patch-stage mycosis fungoides: a clinical study and review of the literature. Photodermatol Photoimmunol Photomed. 2020;36(4):271–7.

    Article  CAS  PubMed  Google Scholar 

  40. •• Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335–41. A meta-analysis of 7 studies including 778 patients with stage IA-IIA MF revealed higher CR rates with PUVA than nbUVB (74% vs. 62%, respectively).

  41. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):22–31.

    Article  CAS  PubMed  Google Scholar 

  42. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159(4):931–5.

    Article  CAS  PubMed  Google Scholar 

  43. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016;127(25):3142–53.

    Article  CAS  PubMed  Google Scholar 

  44. King BJ, Lester SC, Tolkachjov SN, Davis MDP, Gibson LE, Martenson JA. Skin-directed radiation therapy for cutaneous lymphoma: the Mayo Clinic experience. J Am Acad Dermatol. 2020;82(3):634–41.

    Article  PubMed  Google Scholar 

  45. Tandberg DJ, Craciunescu O, Kelsey CR. Radiation therapy for cutaneous T-cell lymphomas. Dermatol Clin. 2015;33(4):703–13.

    Article  CAS  PubMed  Google Scholar 

  46. Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747–53.

    Article  PubMed  Google Scholar 

  47. Cotter GW, Baglan RJ, Wasserman TH, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides–a dose response. Int J Radiat Oncol Biol Phys. 1983;9(10):1477–80.

    Article  CAS  PubMed  Google Scholar 

  48. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8.

    Article  PubMed  Google Scholar 

  49. O’Malley JT, de Masson A, Lowry EL, Giobbie-Hurder A, LeBoeuf NR, Larocca C, et al. Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides. Clin Cancer Res. 2020;26(2):408–18.

    Article  CAS  PubMed  Google Scholar 

  50. Micaily B, Miyamoto C, Kantor G, Lessin S, Rook A, Brady L, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42(2):361–4.

    Article  CAS  PubMed  Google Scholar 

  51. Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364–70.

    Article  PubMed  Google Scholar 

  52. Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol. 2012;166(2):399–404.

    Article  CAS  PubMed  Google Scholar 

  53. Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys. 1995;32(5):1445–9.

    Article  CAS  PubMed  Google Scholar 

  54. Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011;81(4):e651–7.

    Article  PubMed  Google Scholar 

  55. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–92.

    Article  PubMed  Google Scholar 

  56. Kamstrup MR, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys. 2015;92(1):138–43.

    Article  PubMed  Google Scholar 

  57. Song A, Gochoco A, Zhan T, Sahu J, Alpdogan O, Porcu P, et al. A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life. J Am Acad Dermatol. 2020;83(1):78–85.

    Article  CAS  PubMed  Google Scholar 

  58. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.

    Article  CAS  PubMed  Google Scholar 

  59. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.

    CAS  PubMed  Google Scholar 

  60. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168(1):192–200.

  61. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004;51(1):25–32.

    Article  PubMed  Google Scholar 

  62. Amitay-Laish I, Reiter O, Prag-Naveh H, Kershenovich R, Hodak E. Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work? J Dermatolog Treat. 2019;30(3):258–63.

    Article  CAS  PubMed  Google Scholar 

  63. Cheeley J, Sahn RE, DeLong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68(2):247–54.

    Article  CAS  PubMed  Google Scholar 

  64. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J. 2007;13(1):30–9.

    Article  CAS  PubMed  Google Scholar 

  65. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.

    Article  CAS  PubMed  Google Scholar 

  66. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412–6.

    Article  PubMed  Google Scholar 

  67. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91.

    Article  CAS  PubMed  Google Scholar 

  68. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, et al. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015;56(10):2847–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Deschamps O, Ram-Wolff C, Beylot-Barry M, Grange F, Skowron F, Dereure O, et al. Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. Br J Dermatol. 2019;180(2):423–4.

    Article  CAS  PubMed  Google Scholar 

  70. Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, et al. Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous T-cell lymphoma. JAMA Oncol. 2016;2(6):790–3.

    Article  PubMed  Google Scholar 

  71. Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-an overview. Front Med (Lausanne). 2018;5:236.

    Article  Google Scholar 

  72. Wei BM, Hanlon D, Khalil D, Han P, Tatsuno K, Sobolev O, et al. Extracorporeal photochemotherapy: mechanistic insights driving recent advances and future directions. Yale J Biol Med. 2020;93(1):145–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther. 2003;16(4):337–46.

    Article  PubMed  Google Scholar 

  74. Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, et al. Extracorporeal photochemotherapy in mycosis fungoides. Transfus Clin Biol. 2017;24(4):454–7.

    Article  CAS  PubMed  Google Scholar 

  75. Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054–60.

    Article  PubMed  Google Scholar 

  76. Weiner DM, Durgin JS, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches. J Am Acad Dermatol. 2021;84(3):597–604.

    Article  CAS  PubMed  Google Scholar 

  77. Kuhn AK, Bartoo GT, Dierkhising RA, Mara KC, Winters JL, Patnaik MM, et al. Iron deficiency anemia associated with extracorporeal photopheresis: a retrospective analysis. J Clin Apher. 2019;34(6):666–71.

    Article  PubMed  Google Scholar 

  78. Jumbou O, N’Guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999;140(3):427–31.

    Article  CAS  PubMed  Google Scholar 

  79. Spaccarelli N, Rook AH. The use of interferons in the treatment of cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):731–45.

    Article  CAS  PubMed  Google Scholar 

  80. Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.

    Article  CAS  PubMed  Google Scholar 

  81. Sugaya M, Tokura Y, Hamada T, Tsuboi R, Moroi Y, Nakahara T, et al. Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol. 2014;41(1):50–6.

  82. •• Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66. This randomized phase III trial including 97 patients with CD-30-expressing MF found objective global response lasting at least 4 months was greater with brentuximab vedotin (50%) versus physician’s choice of methotrexate or bexarotene (10%).

  83. Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. •• Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204. An open-label, phase III randomized controlled trial of 372 patients with relapsed/refractory MF/SS demonstrated mogamulizumab resulted in greater PFS than vorinostat (8 months vs. 3 months).

  86. Kim YH, Bagot M, Zinzani PL, Duvic M, Morris S, Kim E, et al. Safety of mogamulizumab in mycosis fungoides and Sézary syndrome: final results from the phase 3 Mavoric Study. Blood. 2019;134(Supplement_1):5300-.

  87. Olek-Hrab K, Maj J, Chmielowska E, Jankowska-Konsur A, Olszewska B, Krecisz B, et al. Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients. Eur Rev Med Pharmacol Sci. 2018;22(11):3586–94.

    CAS  PubMed  Google Scholar 

  88. Alenezi F, Girard C, Bessis D, Guillot B, Du-Thanh A, Dereure O. Benefit/risk ratio of low-dose methotrexate in cutaneous lesions of mycosis fungoides and Sezary syndrome. Acta Derm Venereol. 2021;101(2):adv00384.

  89. Wood GS, Wu J. Methotrexate and pralatrexate. Dermatol Clin. 2015;33(4):747–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–22.

    Article  CAS  PubMed  Google Scholar 

  91. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012;12(4):238–43.

    Article  CAS  PubMed  Google Scholar 

  92. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–3.

    Article  CAS  PubMed  Google Scholar 

  93. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51–8.

    Article  CAS  PubMed  Google Scholar 

  94. Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30(33):4091–7.

    Article  CAS  PubMed  Google Scholar 

  95. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–9.

    Article  PubMed  Google Scholar 

  96. •• Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26(1):76–82. This meta-analysis of 5 studies comprising 266 patients with CTCL found allogeneic hematopoeitic stem cell transplantation resulted in a pooled overall survival of 59% and PFS of 36%. Pooled relapse rate was 47% and nonrelapse mortality was 19%.

  97. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Clinicaltrials.gov. FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Available from: https://clinicaltrials.gov/ct2/show/NCT02448381?term=hypericin&cond=Mycosis+Fungoides&draw=2&rank=1.

  99. Clinicaltrials.gov. IPH4102 alone or in combination with chemotherapy in patients with advanced T cell lymphoma (TELLOMAK) [Available from: https://clinicaltrials.gov/ct2/show/NCT03902184?term=KIR3DL2&cond=Mycosis+Fungoides&draw=2&rank=2.

  100. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–70.

    Article  CAS  PubMed  Google Scholar 

  101. Clinicaltrials.gov. Resminostat for maintenance treatment of patients with advanced stage mycosis fungoides (MF) or Sézary syndrome (SS) (RESMAIN) [Available from: https://clinicaltrials.gov/ct2/show/NCT02953301?term=resminostat&cond=mycosis+fungoides&draw=2&rank=1.

  102. Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  103. Clinicaltrials.gov. Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T cell lymphoma [Available from: https://clinicaltrials.gov/ct2/show/NCT03011814?term=durvalumab&cond=mycosis+fungoides&draw=2&rank=1.

  104. Perez C, Mondejar R, Garcia-Diaz N, Cereceda L, Leon A, Montes S, et al. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-kappaB and nuclear factor of activated T cells pathways. Br J Dermatol. 2020;182(1):147–55.

    CAS  PubMed  Google Scholar 

  105. Horwitz SM, Feldman TA, Hess BT, Khodadoust MS, Youn H. Kim, et al. The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood 2018; 132 (Supplement 1): 1001.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA

    Caitlin M. Brumfiel MS, Meera H. Patel BS, Pranav Puri BS, Jake Besch-Stokes BS, David J. DiCaudo MD, Mark R. Pittelkow MD & Aaron R. Mangold MD

  2. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

    Scott Lester MD

  3. Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA

    William G. Rule MD

  4. Division of Hematology Oncology, Mayo Clinic, Phoenix, AZ, USA

    Nandita Khera MD & Allison C. Rosenthal DO

  5. Department of Dermatology, Mayo Clinic, Jacksonville, FL, USA

    Jason C. Sluzevich MD

  6. Department of Dermatology, Mayo Clinic, Rochester, MN, USA

    Nneka Comfere MD

  7. Division of Hematology Oncology, Mayo Clinic, Rochester, MN, USA

    N. Nora Bennani MD

Authors
  1. Caitlin M. Brumfiel MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meera H. Patel BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pranav Puri BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jake Besch-Stokes BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scott Lester MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William G. Rule MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nandita Khera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jason C. Sluzevich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David J. DiCaudo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nneka Comfere MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N. Nora Bennani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Allison C. Rosenthal DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mark R. Pittelkow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Aaron R. Mangold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron R. Mangold MD.

Ethics declarations

Conflict of Interest

Caitlin M. Brumfiel declares that she has no conflict of interest. Meera H. Patel declares that she has no conflict of interest. Pranav Puri declares that he has no conflict of interest. Jake Besch-Stokes declares that he has no conflict of interest. Scott Lester declares that he has no conflict of interest. William G. Rule declares that he has no conflict of interest. Nandita Khera declares that she has no conflict of interest. Jason C. Sluzevich declares that he has no conflict of interest. David J. DiCaudo declares that he has no conflict of interest. Nneka Comfere declares that she has no conflict of interest. N. Nora Bennani currently serves on advisory boards for Verastem Oncology, Acrotech Biopharma, Kyowa Kirin, and Daiichi-Sankyo. Allison C. Rosenthal declares that she has no conflict of interest. Mark R. Pittelkow declares that he has no conflict of interest. Aaron R. Mangold has received institutional research funding from Kyowa Kirin, Miragen Therapeutics, Regeneron Pharmaceuticals, Corbus Pharmaceuticals, Sun Pharmaceutical Industries, Incyte, Pfizer, Eli Lilly, Elorac Pharmaceuticals, Novartis, Janssen, Soligenix, the American Society for Dermatologic Surgery, and the Dermatology Foundation; has received compensation for service as a consultant from Kyowa Kirin, Eli Lilly, Momenta Pharmaceuticals, UCB, Regeneron Pharmaceuticals, Genentech, and PHELEC.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brumfiel, C.M., Patel, M.H., Puri, P. et al. How to Sequence Therapies in Mycosis Fungoides. Curr. Treat. Options in Oncol. 22, 101 (2021). https://doi.org/10.1007/s11864-021-00899-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00899-0

Keywords

Search

Navigation